autoimmune disease; autoimmune disease with interstitial lung disease; This serious case was reported by a pharmacist via call center representative and described the occurrence of autoimmune disorder in a elderly female patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 2nd dose of Shingrix and the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix and Shingrix, the patient experienced autoimmune disorder (Verbatim: autoimmune disease) (serious criteria GSK medically significant) and interstitial lung disease (Verbatim: autoimmune disease with interstitial lung disease) (serious criteria GSK medically significant). The patient was treated with rituximab (Rituxan). The outcome of the autoimmune disorder and interstitial lung disease were unknown. It was unknown if the reporter considered the autoimmune disorder and interstitial lung disease to be related to Shingrix and Shingrix. The company considered the autoimmune disorder and interstitial lung disease to be unrelated to Shingrix and Shingrix. Additional Information: GSK Receipt Date: 08-JAN-2025 Pharmacist stated she had a patient that completed Shingrix series in 2020. The patient had an autoimmune disease with interstitial lung disease and was receiving Rituxin infusions. Pharmacist stated she really was not sure if the autoimmune disease was present before Shingrix series was administered, but she thought it was a newer development as the Rituxin was new for the patient. The pharmacist could no longer recall the name of the patient, so she was unable to look in the patient’s records to locate the exact date of Shingrix doses. The only patient specific information the pharmacist could provide was that this was a female patient in her 80s. The patient decided to not receive any further Shingrix dosing. The pharmacist was inquiring about recommendations on repeating the series in patients receiving Rituxin, as the patient’s physician had mentioned finding guidelines that advised repeating. Following an internal meeting on 15-January-2025, it was realized that clarification was needed to determine if the autoimmune condition with interstitial lung disease was pre-existing, or occurred after the Shingrix series, so an outbound call was placed back to the pharmacist on 15- January -2025. The vaccine administration facility was the same as primary reporter.; Sender’s Comments: Autoimmune disorder and Interstitial lung disease are unlisted events which are considered unrelated to GSK vaccine Shingrix (Dose 1 & 2).